BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha AND Treatment
77 results:

  • 1. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in leukemia.
    Pandey S; Singh R; Habib N; Tripathi RM; Kushwaha R; Mahdi AA
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1121-1134. PubMed ID: 38679971
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
    Yadav AK; Wang S; Shin YM; Jang BC
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Mechanism of Procyanidin B2 in the treatment of Chronic Myeloid leukemia Based on Integrating Network Pharmacology and Molecular Docking.
    Li HX; Jing YX; Chai YH; Sun XH; He XX; Xue SL; Xi YM; Ma XL
    Anticancer Agents Med Chem; 2023; 23(16):1838-1847. PubMed ID: 37246327
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.
    Gayatri MB; Kancha RK; Patchva D; Velugonda N; Gundeti S; Reddy ABM
    FEBS J; 2023 Sep; 290(18):4480-4495. PubMed ID: 37171230
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca 2+ -dependent gap junction intercellular communication.
    Li X; Xiao Y; Wang X; Huang R; Wang R; Deng Y; Rao J; Gao Q; Yang S; Zhang X
    Chin Med J (Engl); 2023 Jan; 136(2):194-206. PubMed ID: 36801891
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Gene expression of carbonic anhydrase 9 (CA9) in
    Alyaqubi KJ; Dosh RH; Al-Fatlawi RB; Al-Rehemi SM; Hadi NR
    J Med Life; 2022 Sep; 15(9):1158-1163. PubMed ID: 36415514
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia.
    Zhou H; Jiang Y; Huang Y; Zhong M; Qin D; Xie C; Pan G; Tan J; Deng M; Zhao H; Zhou Y; Tang Y; Lai Q; Fang Z; Luo Y; Jiang Y; Xu B; Zha J
    Cancer Lett; 2023 Feb; 554():215997. PubMed ID: 36396101
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2.
    Ma HN; Chen HJ; Liu JQ; Li WT
    Cell Death Dis; 2022 Jul; 13(7):625. PubMed ID: 35853854
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Action Sites and Clinical Application of HIF-1α Inhibitors.
    Xu R; Wang F; Yang H; Wang Z
    Molecules; 2022 May; 27(11):. PubMed ID: 35684364
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1
    Zhang Y; Chen H; Shen Y; Zhou X
    J Immunol Res; 2022; 2022():6324326. PubMed ID: 35528614
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Far-infrared radiation alleviates cisplatin-induced vascular damage and impaired circulation via activation of HIF-1α.
    Chen CH; Chen MC; Hsu YH; Chou TC
    Cancer Sci; 2022 Jun; 113(6):2194-2206. PubMed ID: 35411640
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Effect of Hypoxia Inducible Factor-1α on Chemosensitivity of B-ALL Cells to Vincristine and Its Mechanism].
    Xiang CL; Shi YY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):386-392. PubMed ID: 35395968
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes.
    Zhu JY; Huang X; Fu Y; Wang Y; Zheng P; Liu Y; Han Z
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34580712
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Effect of Mimic Hypoxia on the Proliferation and Expression of miR-27a, miR-9, miR-370 and their Target Genes in MOLT-4 and KG1a Cell Lines.
    Emaogolizadeh Gurd Tapeh B; Mohammadi A; Alivand MR; Solali S
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1975-1984. PubMed ID: 34181359
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. CXCL2 benefits acute myeloid leukemia cells in hypoxia.
    Li L; Zhao L; Man J; Liu B
    Int J Lab Hematol; 2021 Oct; 43(5):1085-1092. PubMed ID: 33793061
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Immunomodulatory Effect of Green Tea treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid leukemia Patients with Myelodysplasia-related Changes.
    Calgarotto AK; Longhini AL; Pericole de Souza FV; Duarte ASS; Ferro KP; Santos I; Maso V; Olalla Saad ST; Torello CO
    Integr Cancer Ther; 2021; 20():15347354211002647. PubMed ID: 33754891
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.
    Fahy L; Calvo J; Chabi S; Renou L; Le Maout C; Poglio S; Leblanc T; Petit A; Baruchel A; Ballerini P; Naguibneva I; Haddad R; Arcangeli ML; Mazurier F; Pflumio F; Uzan B
    Blood Adv; 2021 Jan; 5(2):513-526. PubMed ID: 33496749
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
    Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
    Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Repurposing of Acriflavine to Target Chronic Myeloid leukemia treatment.
    Nehme R; Hallal R; El Dor M; Kobeissy F; Gouilleux F; Mazurier F; Zibara K
    Curr Med Chem; 2021; 28(11):2218-2233. PubMed ID: 32900342
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.